Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies

Webinar recorded on June 21, 2022
Hosted by Formulary Decisions

Cell and gene therapies promise to potentially transform the management of devastating and life-threatening chronic diseases for many patients.  However, life sciences companies developing these innovative therapies continue to face reimbursement and patient access challenges.  Join us as we review several approved and numerous investigational cell and gene therapies, and discuss potential strategies for cell and gene therapy companies to consider that may help mitigate these challenges.

In this session, our expert panel will:

• Summarize approved and investigational cell and gene therapies in late-stage development
• Discuss common reimbursement and access challenges for cell and gene therapies, including payment methodologies, correct coding, and billing
• Review an inpatient case study for Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel)

Download Slides

Moderator:

Tasmina Hydery, PharmD, MBA, BCGP
Assistant Director, Integrated Technology Solutions
Xcenda

Speakers:

Milda Kaitz, CPC, CPC-I, CPMA
Associate Director, Reimbursement & Policy Insights
Xcenda

Pavel Lavitas, PharmD, BCPS
Consultant Pharmacists Team Lead
Commonwealth Medicine - UMass Chan Medical School